Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic
  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

SHAREHOLDER ALERT: KPLT SPPI ZEV: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

NEW YORK, NY / ACCESSWIRE / October 20, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Katapult Holdings, Inc. (NASDAQ:KPLT)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/katapult-holdings-inc-loss-submission-form?prid=20557&wire=1
Lead Plaintiff Deadline: October 26, 2021
Class Period: December 18, 2020 - August 10, 2021

Allegations against KPLT include that: (1) Katapult was experiencing declining e-commerce retail sales and consumer spending, (2) despite Katapult's assertions that it was clear and compelling value proposition to both consumers and merchants, transforming the way nonprime consumers shop for essential goods and enabling merchant access to this underserved segment, Katapult lacked visibility into its consumers' future buying behavior; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/spectrum-pharmaceuticals-inc-loss-submission-form?prid=20557&wire=1
Lead Plaintiff Deadline: November 1, 2021
Class Period: December 27, 2018 - August 5, 2021

Allegations against SPPI include that: (i) the manufacturing facility for ROLONTIS, an investigational granulocyte-colony stimulating factor analog, maintained deficient controls and/or procedures; (ii) the foregoing deficiencies decreased the likelihood that the Food and Drug Administration would approve the ROLONTIS biologics license application ("BLA") in its current form; (iii) Spectrum had therefore materially overstated the ROLONTIS BLA's approval prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Lightning Emotors, Inc (NYSE:ZEV)

If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/lightning-emotors-inc-loss-submission-form?prid=20557&wire=1
Lead Plaintiff Deadline: December 15, 2021
Class Period: May 7, 2021 - August 16, 2021

Allegations against ZEV include that: (i) the Company would record a substantially greater net loss per share in the second quarter of 2021 compared to the second quarter of 2020 and would pull its full year guidance for the remainder of 2021; (ii) accordingly, the Company materially overstated its financial position and/or prospects; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong



View source version on accesswire.com:
https://www.accesswire.com/668881/SHAREHOLDER-ALERT-KPLT-SPPI-ZEV-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.